Pyridine

Pyridine

SCHEMBL367049

ClCCCl.c1ccncc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.64
NAPRT Q6XQN6 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
ALDH1A1 P00352 1/20 0.36
NOTUM Q6P988 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL30378 0.89
Pyridine SCHEMBL6160661 0.86 TSHR (0.64) TSHRNAPRTTDP1NOTUM
Pyridine SCHEMBL28322715 0.86 TSHR (0.64) TSHRNAPRTTDP1NOTUM
Pyridine SCHEMBL31396433 0.84
Pyridine SCHEMBL28109394 0.84 TSHR (0.53) TSHRNAPRTTDP1
Pyridine SCHEMBL29013612 0.84 TSHR (0.53) TSHRNAPRTTDP1ALDH1A1
Pyridine SCHEMBL9011063 0.84 TSHR (0.53) TSHRNAPRTTDP1
Pyridine SCHEMBL1389381 0.84 TDP1 (0.53) TSHRNAPRTTDP1ALDH1A1
Pyridine SCHEMBL11485834 0.83 TSHR (0.60) TSHRNAPRTTDP1NOTUM
Pyridine SCHEMBL1095589 0.83 NAPRT (0.60) TSHRNAPRTTDP1ALDH1A1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120136189-A1 BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION CONOCOPHILLIPS COMPANY - IP SERVICES GROUP (US) 2012-05-31 US claimed
US-20110185788-A1 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY KOCH PETER 2011-08-04 US claimed
EP-2275090-A2 Microparticles prepared using an ionic liquid Novartis AG (CH) 2011-01-19 EP claimed
US-20100239524-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID NOVARTIS AG (CH) 2010-09-23 US claimed
US-7569149-B2 Ionic liquids as solvents in headspace gas chromatography NOVARTIS AG (CH) 2009-08-04 US claimed
US-20060147532-A1 Microparticles prepared using an ionic liquid AUSBORN MICHAEL 2006-07-06 US claimed
US-20050205493-A1 Ionic liquids as solvents in headspace gas chromatography NOVARTIS AG (CH) 2005-09-22 US claimed
EP-1569621-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID Novartis AG (CH) 2005-09-07 EP claimed
EP-1529205-A2 ANALYTICAL PROCESS Novartis AG (CH) 2005-05-11 EP claimed
WO-2004052340-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID NOVARTIS AG (CH) 2004-06-24 WO claimed
WO-2004013612-A2 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY NOVARTIS AG (CH) 2004-02-12 WO claimed
WO-2000040673-A1 INDUSTRIAL PROCESS AND CATALYSTS THE SECRETARY OF STATE FOR DEFENCE (GB) 2000-07-13 WO claimed
US-5994602-A IN THE PRESENCE OF A HYDROCARBYL ALUMINUM OR GALLIUM HALIDE AND A HYDROCARBYL-SUBSTITUTED IMIDAZOLIUM OR PYRIDINIUM HALIDE BP CHEMICALS LIMITED (GB) 1999-11-30 US claimed
WO-1998047616-A1 CATALYST COMPRISING A BUFFERED IONIC LIQUID AND HYDROCARBON CONVERSION PROCESS, E.G. OLIGOMERISATION BP CHEMICALS LIMITED (GB) 1998-10-29 WO claimed
EP-0693045-B1 ALKYLATION PROCESS BP CHEM INT LTD (GB) 1997-10-22 EP claimed
EP-0791643-A1 Lubricating oils BP Chemicals Limited (GB) 1997-08-27 EP claimed
EP-0693045-A1 ALKYLATION PROCESS BP CHEM INT LTD (GB) 1996-01-24 EP claimed
WO-1995021806-A1 ALKYLATION PROCESS BP CHEMICALS LIMITED (GB) 1995-08-17 WO claimed
WO-1995021872-A1 IONIC LIQUIDS BP CHEMICALS LIMITED (GB) 1995-08-17 WO claimed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
EP-2593403-B1 METHOD FOR PRODUCING A GEL FILM AND FILTRATION MEMBRANE PREPARED WITH THIS METHOD UNIV MONASH (AU) 2020-03-04 EP disclosed
CN-110234627-A Pyridinone compounds and agricultural or horticultural use fungicide using pyridinone compounds as effective component 三井化学AGRO株式会社 2019-09-13 CN disclosed
US-10297396-B2 Graphene-based films MONASH UNIVERSITY (AU) 2019-05-21 US disclosed
US-9751763-B2 Material and applications therefor MONASH UNIVERSITY (AU) 2017-09-05 US disclosed
CN-106363170-A Three-dimensionally shaped article and three-dimensionally shaping method 精工爱普生株式会社 2017-02-01 CN disclosed
US-20160016804-A1 GRAPHENE-BASED FILMS MONASH UNIVERSITY (AU) 2016-01-21 US disclosed
EP-2964572-A1 GRAPHENE-BASED FILMS Monash University (AU) 2016-01-13 EP disclosed
CN-103880727-B A kind of halo sulphur compound and its preparation method and application LUZHOU DONGFANG AGROCHEMICAL CO., LTD. (CN) 2016-01-13 CN disclosed
WO-2014134663-A1 GRAPHENE-BASED FILMS MONASH UNIVERSITY (AU) 2014-09-12 WO disclosed
CN-103694122-A 2,2',4,4',6,6'-hexanitro diphenylethylene preparation method XIAN MODERN CHEMISTRY RES INST 2014-04-02 CN disclosed
US-20130180912-A1 MATERIAL AND APPLICATIONS THEREFOR MONASH UNIVERSITY (AU) 2013-07-18 US disclosed
EP-2593403-A1 MATERIAL AND APPLICATIONS THEREFOR Monash University (AU) 2013-05-22 EP disclosed
CN-103102349-A Protein kinase inhibitor and composition and application thereof BEIJING CENTAURUS BIOPHARMA TECHNOLOGY CO LTD 2013-05-15 CN disclosed
US-8276664-B2 Well treatment operations using spherical cellulosic particulates BAKER HUGHES INCORPORATED (US) 2012-10-02 US disclosed
US-20120220775-A1 ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES LOHSE OLIVIER (FR) 2012-08-30 US disclosed
US-20120136189-A1 BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION CONOCOPHILLIPS COMPANY - IP SERVICES GROUP (US) 2012-05-31 US disclosed
EP-2414335-A2 A PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE Glenmark Generics Limited (IN) 2012-02-08 EP disclosed
US-20120022047-A1 PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE GLENMARK GENERICS LTD (IN) 2012-01-26 US disclosed
WO-2012006657-A1 MATERIAL AND APPLICATIONS THEREFOR MONASH UNIVERSITY (AU) 2012-01-19 WO disclosed
WO-2011112514-A1 BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION CONOCOPHILLIPS COMPANY (US) 2011-09-15 WO disclosed
US-20110185788-A1 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY KOCH PETER 2011-08-04 US disclosed
EP-1613599-B8 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2011-06-22 EP disclosed
US-20110140885-A1 SENSOR FOR CONTAINER MONITORING SYSTEM HUMMER GREGORY J 2011-06-16 US disclosed
CN-102089311-A Morphinan synthesis process PHOENIX PHARMALABS INC 2011-06-08 CN disclosed
EP-2275090-A2 Microparticles prepared using an ionic liquid Novartis AG (CH) 2011-01-19 EP disclosed
EP-1613599-B1 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2010-12-15 EP disclosed
WO-2010113179-A2 A PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE GLENMARK GENERICS LIMITED (IN) 2010-10-07 WO disclosed
US-20100239524-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID NOVARTIS AG (CH) 2010-09-23 US disclosed
EP-1791820-B1 ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES NOVARTIS AG (CH) 2009-12-02 EP disclosed
US-7605267-B2 Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones NOVARTIS AG (CH) 2009-10-20 US disclosed
US-20090199622-A1 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY KOCH PETER 2009-08-13 US disclosed
US-7569149-B2 Ionic liquids as solvents in headspace gas chromatography NOVARTIS AG (CH) 2009-08-04 US disclosed
US-20090054653-A1 ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE LOHSE OLIVIER 2009-02-26 US disclosed
US-20090044942-A1 Cellulosic Particulates and Method of Manufacture and Use Thereof BJ SERVICES COMPANY 2009-02-19 US disclosed
EP-1791820-A2 ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES Novartis AG (CH) 2007-06-06 EP disclosed
US-20060189653-A1 Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones NOVARTIS AG (CH) 2006-08-24 US disclosed
US-20060147532-A1 Microparticles prepared using an ionic liquid AUSBORN MICHAEL 2006-07-06 US disclosed
CN-1774423-A Process for the preparation of 5- (haloacetyl) -8- (substituted oxy) - (1H) -quinolin-2-ones NOVARTIS AG (CH) 2006-05-17 CN disclosed
EP-1613599-A1 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES Novartis AG (CH) 2006-01-11 EP disclosed
WO-2005123684-A2 ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE NOVARTIS AG (CH) 2005-12-29 WO disclosed
US-20050205493-A1 Ionic liquids as solvents in headspace gas chromatography NOVARTIS AG (CH) 2005-09-22 US disclosed
EP-1569621-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID Novartis AG (CH) 2005-09-07 EP disclosed
EP-1529205-A2 ANALYTICAL PROCESS Novartis AG (CH) 2005-05-11 EP disclosed
WO-2004087668-A1 A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-QUINOLIN-2-ONES NOVARTIS AG (CH) 2004-10-14 WO disclosed
WO-2004052340-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID NOVARTIS AG (CH) 2004-06-24 WO disclosed
WO-2004013612-A2 IONIC LIQUIDS AS SOLVENTS IN HEADSPACE GAS CHROMATOGRAPHY NOVARTIS AG (CH) 2004-02-12 WO disclosed
CN-1058694-C Alkylation process BP CHEM INT LTD (GB) 2000-11-22 CN disclosed
WO-2000041809-A1 IONIC LIQUID CATALYST FOR ALKYLATION BP CHEMICALS LIMITED (GB) 2000-07-20 WO disclosed
US-5994602-A IN THE PRESENCE OF A HYDROCARBYL ALUMINUM OR GALLIUM HALIDE AND A HYDROCARBYL-SUBSTITUTED IMIDAZOLIUM OR PYRIDINIUM HALIDE BP CHEMICALS LIMITED (GB) 1999-11-30 US disclosed
WO-1998047616-A1 CATALYST COMPRISING A BUFFERED IONIC LIQUID AND HYDROCARBON CONVERSION PROCESS, E.G. OLIGOMERISATION BP CHEMICALS LIMITED (GB) 1998-10-29 WO disclosed
US-5691053-A Coating composition with thermally-influenced color DAIMLER-BENZ AG (DE) 1997-11-25 US disclosed
EP-0693045-B1 ALKYLATION PROCESS BP CHEM INT LTD (GB) 1997-10-22 EP disclosed
EP-0791643-A1 Lubricating oils BP Chemicals Limited (GB) 1997-08-27 EP disclosed
CN-1123023-A Alkylation process BP CHEM INT LTD (GB) 1996-05-22 CN disclosed
EP-0558187-B1 Butene polymers BP CHEM INT LTD (GB) 1996-04-10 EP disclosed
EP-0693045-A1 ALKYLATION PROCESS BP CHEM INT LTD (GB) 1996-01-24 EP disclosed
WO-1995021872-A1 IONIC LIQUIDS BP CHEMICALS LIMITED (GB) 1995-08-17 WO disclosed
WO-1995021806-A1 ALKYLATION PROCESS BP CHEMICALS LIMITED (GB) 1995-08-17 WO disclosed
US-5304615-A Aluminium compounds with imidazolium and pyridinium halides BP CHEMICALS LIMITED (GB) 1994-04-19 US disclosed
EP-0558187-A1 Butene polymers BP Chemicals Limited (GB) 1993-09-01 EP disclosed
EP-0558187-A1 Butene polymers BP Chemicals Limited (GB) 1993-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS CRBN, CDR2, MDM2 TSHR 3035/4885NAPRT 2808/4885TDP1 1939/4885
US-20120022047-A1 PROCESS FOR THE PURIFICATION OF ESLICARBAZEPINE ACETATE CACNA1A, GABRE, CACNA1D TSHR 3720/4885NAPRT 3405/4885TDP1 4490/4885
US-20090054653-A1 ENANTIOSELEKTIVE PREPARATION OF QUINOLINE DERIVATIVE HAX1, OPRK1, OPRD1 TSHR 2165/4885NAPRT 2501/4885TDP1 1997/4885
US-20100239524-A1 MICROPARTICLES PREPARED USING AN IONIC LIQUID FIBP, MIF, CHMP4B TSHR 3760/4885NAPRT 4128/4885TDP1 1587/4885
US-20120136189-A1 BUFFERED IONIC LIQUIDS FOR OLEFIN DIMERIZATION OSBPL8, OSBP, OSBP2 TSHR 2589/4885NAPRT 2710/4885TDP1 2022/4885
US-20120220775-A1 ENANTIOSELECTIVE PREPARATION OF QUINOLINE DERIVATIVES OPRM1, OPRD1, HAX1 TSHR 2128/4885NAPRT 2561/4885TDP1 2185/4885
US-20060189653-A1 Process for the preparation of 5-(halocetyl)-8-(substituted oxy)-(1h)-quinolin-2-ones UGT8, KAT8, UGT1A8 TSHR 1260/4885NAPRT 1072/4885TDP1 3103/4885
US-20060147532-A1 Microparticles prepared using an ionic liquid FIBP, MIF, CHMP4B TSHR 3760/4885NAPRT 4128/4885TDP1 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.